Extended Data Fig. 3: Minimal residual disease concordance of candidate variants.

Median concordance of candidate variants when selecting the 16 somatic mutations with the highest VAF for MRD monitoring in primary tumor and plasma baseline samples within the discovery cohort (left, n = 12 patients) and the validation cohort (right, n = 14 patients). Two-sided Wilcoxon test; p-value = 0.047.